Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity
- 19 January 2016
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 35 (4) , 2045-2052
Abstract
Hypoxia-inducible factor 1 (HIF-1), a heterodimeric transcription factor that mediates the adaptation of tumor cells and tissues to the hypoxic microenvironment, has attracted considerable interest as a potential therapeutic target. Kamebakaurin is a diterpenoid compound isolated from Isodon excia (Maxin.) Hara, which has been used for anti-inflammatory activities. However, its antitumor activity along with molecular mechanism has not been reported. Kamebakaurin showed potent inhibitory activity against HIF-1 activation induced by hypoxia or CoCl2 in various human cancer cell lines. This compound significantly decreased the hypoxia-induced accumulation of HIF-1α protein, whereas it did not affect the expression of topoisomerase-I (Topo-I). Further analysis revealed that kamebakaurin inhibited HIF-1α protein synthesis, without affecting the expression level of HIF-1α mRNA or degradation of HIF-1α protein. Furthermore, kamebakaurin prevented hypoxia-induced expression of HIF-1 target genes for vascular endothelial growth factor (VEGF) and erythropoietin (EPO). However, kamebakaurin caused cell growth inhibition via cell cycle arrest at G1 phase in tumor cells. In vivo studies, we further confirmed the inhibitory effect of kamebakaurin on the expression of HIF-1α proteins, leading to growth inhibition of HCT116 cells in a xenograft tumor model. These results show that kamebakaurin is an effective inhibitor of HIF-1 and provide new perspectives into its anticancer activity.Keywords
This publication has 21 references indexed in Scilit:
- Extravasation of polymeric nanomedicines across tumor vasculatureAdvanced Drug Delivery Reviews, 2011
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsOncogene, 2009
- Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy responseNature Reviews Cancer, 2008
- The role of hypoxia-inducible factors in tumorigenesisCell Death & Differentiation, 2008
- Hypoxia and cancerJournal of Molecular Medicine, 2007
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl HydroxylationScience, 2001
- Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.Proceedings of the National Academy of Sciences, 1995
- Purification and Characterization of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 1995